title: Management of secondary immune deficiencies: what is the role of immunoglobulins?
authors.affiliation: Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, 27 rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France.
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Fermand
authors.forename: Jacques-Eric
authors.initials: JE
authors.lastname: Gottenberg
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000009:adverse effects / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D064420:Drug-Related Side Effects and Adverse Reactions; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000209:etiology / Q000628:therapy*; D007165:Immunosuppression Therapy / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D019138:Antibodies, Blocking; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab